DBV Technologies Stock Rebounds on its €2.75 Support Following the VITESSE Study
The French biotech regains momentum in a well-oriented Parisian market. The stock attempts to stabilize its price after several weeks of significant decline, as new clinical data on its peanut allergy patch were unveiled at the beginning of the week.
A Technical Rebound with an RSI at 29, at the Lower End of Recent Ranges
DBV Technologies stock has risen by 1.52% to €2.80, in a SBF 120 that is up by 0.79%. The stock has recovered from the support threshold of €2.75, tested at the start of the session, while an RSI at 29 indicates seller exhaustion over the last few weeks. However, the biotech remains below its three moving averages, with the MM50 at €3.37, making the price 16.97% lower than this average.
Over a month, the decline reaches nearly 18%, and exceeds 30% over three months, which places today's rebound in a still largely bearish dynamic. Over twelve months, however, the performance remains positive, at more than 73%.
Positive Data from the VITESSE Study and Presentation of the THRIVE Protocol at EAACI
On Monday, the company released new positive data from the phase 3 VITESSE study on its epicutaneous immunotherapy patch for children allergic to peanuts. The phase 2 THRIVE study protocol, which expands the evaluation to infants aged 6 to 12 months, will also be presented at the 2026 Congress of the European Academy of Allergy and Clinical Immunology, from June 12 to 15 in Istanbul. This scientific event occurs as CEO Daniel Tassé spoke on Tuesday at the Global Healthcare Conference by Goldman Sachs in Miami.
